Johnson & Johnson offers $5.5 billion to settle 76,000 talc cancer lawsuits, ending decade-long battle
The pharmaceutical giant aims to end a decade-long legal battle with a $5.5 billion offer that covers nearly all remaining talc claims in the United States, while a separate UK lawsuit continues.
The settlement offer
Johnson & Johnson announced on Monday it would pay up to $5.5 billion to resolve about 76,000 claims alleging its talc-based products caused ovarian cancer. The proposal covers nearly all remaining talc litigation against the New Jersey-based company, including cases consolidated in federal court and related state court actions. The deal requires acceptance by 95% of ovarian cancer claimants before it becomes final. J&J expects to pay $3 billion in 2027, with further payments in 2028, though the total could rise depending on participation. Chris Seeger, a lawyer representing about 2,500 claimants, said the company could ultimately pay $7 billion or more.
We got a fair settlement, and our clients are going to be happy with it.
The allegations and J&J's denial
Plaintiffs allege that J&J's baby powder and other talc products caused ovarian cancer or mesothelioma. The company has consistently denied the claims, calling them meritless. Erik Haas, J&J's vice-president of litigation, said the settlement allows the firm to move forward without admitting fault.
While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives.
J&J stopped selling talc-based baby powder in the United States and Canada in 2020 and halted worldwide sales in 2023. In 2024 the World Health Organization classified talc as "probably carcinogenic to humans".
Legal history and recent verdicts
The first US jury verdict came in 2016, ordering J&J to pay $72 million to the family of a woman who died of ovarian cancer; that ruling was overturned a year later. Claims multiplied afterward. In October 2025 a California jury awarded $966 million to the family of a deceased woman who attributed her cancer to decades of using J&J baby powder, the largest single-plaintiff award in the litigation. J&J had already set aside $11 billion in provisions in June 2026, and Bloomberg Intelligence estimates total settlement costs at $10 billion to $12 billion.
- First US jury orders J&J to pay $72m to family of woman who died of ovarian cancer; verdict overturned a year later.
- J&J stops selling talc-based baby powder in the United States and Canada.
- J&J halts worldwide sales of talc-based baby powder.
- World Health Organization classifies talc as 'probably carcinogenic to humans'.
- California jury awards $966m to family of a woman who died of cancer she attributed to J&J baby powder.
- UK lawsuit filed, later described as the largest product liability case in UK history.
- J&J sets aside $11bn in provisions for talc litigation.
- J&J announces $5.5bn settlement offer covering about 76,000 claims.
UK lawsuit
A separate case is proceeding in the United Kingdom. Filed in 2025, it is described as the largest product liability case in UK history, covering more than 7,000 potential claimants according to Al Jazeera (other reports cite over 3,000 complainants). The claim alleges J&J knew its talc could cause cancers but continued selling the product. Compensation could exceed £1 billion (€1.17 billion). J&J denies the allegations.
Market reaction and next steps
J&J shares rose 1.1% in after-hours trading in New York following the announcement. The settlement is not yet final; it hinges on the 95% claimant acceptance threshold. The company said the agreement provides an efficient conclusion to the litigation and allows it to focus on its core pharmaceutical and medical-device businesses.
